GlassScriptPhysician profile
Norman Sowell
NPI 1649959941
$3,637.61
in general payments reported to CMS, 2019-2025
21 companies · $2,172 in 2025
The $2,172 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,466 · 2025: $2,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,417 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,416.63 |
| Education | $220.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $706.57 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $495.98 | 2024-2025 | |
| Lundbeck LLC | $414.35 | 2024-2025 | Abilify Asimtufii, Rexulti |
| Otsuka America Pharmaceutical, INC. | $410.17 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $322.03 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $308.43 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Indivior INC. | $169.79 | 2024-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $167.58 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $126.86 | 2024-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.86 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $80.15 | 2024-2025 | Ingrezza |
| Tris Pharma INC | $59.43 | 2024-2025 | Onyda Xr, Dyanavel Xr |
| Noven Therapeutics, LLC | $48.78 | 2024-2025 | Xelstrym, Secuado |
| Corium, LLC | $47.87 | 2025 | Azstarys |
| Medtronic, INC. | $37.27 | 2025 | Corevalve Evolut R |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $35.43 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.18 | 2024-2025 | Trintellix |
| Braeburn INC. | $25.65 | 2025 | Brixadi |
| Bausch Health US, LLC | $14.74 | 2024 | Aplenzin |
| Axsome Therapeutics, INC. | $13.26 | 2024 | Auvelity |
| Neos Therapeutics, LP | $13.23 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Sowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.